Silymarin for treatment of adults with nonalcoholic fatty liver disease

Wang, Caie; Kanaan, Ghid; Shang, Yiyang; Chai, Lu; Li, Hui; Qi, Xingshun

doi:10.1002/14651858.cd015524

Cochrane Database of Systematic Reviews

2023

DOI: 10.1002/14651858.cd015524

|View full text |Cite

Silymarin for treatment of adults with nonalcoholic fatty liver disease

Caie Wang

Ghid Kanaan

Yiyang Shang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study

Fang,

Yin,

Zhao

et al. 2024

Front. Med.

View full text Add to dashboard Cite

PurposeChronic hepatitis B (CHB) and fatty liver disease (FLD) are common chronic liver diseases, both of which can progress to advanced liver diseases with poor outcome. However, it remains controversial whether the presence of FLD aggravates the disease severity of CHB patients.Patients and methodsAll consecutive outpatients who were diagnosed with CHB at our department between March 1, 2021 and September 30, 2023 were retrospectively screened. They were divided into FLD and non-FLD groups. Liver function parameters and non-invasive indicators of liver fibrosis, including liver stiffness measurement (LSM) value, fibrosis-4 index (FIB-4) score, and aspartate aminotransferase to platelet ratio index (APRI) score, were compared between the two groups. Subgroups analyses were performed in HBeAg-positive, HBeAb-positive, HBV DNA > 10 IU/mL, mild FLD, and moderate/severe FLD patients.ResultsOverall, 201 CHB patients were included, of whom 76 (37.81%) had FLD. In the overall analyses, CHB patients with FLD had a significantly higher alanine aminotransferase (ALT) (47.04 ± 53.28 vs. 32.95 ± 35.10, p = 0.003) than those without FLD, but there was no significant difference in the LSM value (7.79 ± 5.16 vs. 8.19 ± 4.99, p = 0.508), FIB-4 score (1.13 ± 0.75 vs. 1.28 ± 0.99, p = 0.679), and APRI score (0.41 ± 0.46 vs. 0.36 ± 0.47, p = 0.535) between CHB patients with and without FLD. The above-mentioned statistical results in all subgroup analyses were nearly consistent with those in the overall analyses.ConclusionFLD may intensify abnormal liver function reflected by increased ALT level in CHB patients, but not influence the progression of liver fibrosis.

show abstract

Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study

Fang,

Yin,

Zhao

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Silymarin for treatment of adults with nonalcoholic fatty liver disease

Cited by 1 publication

References 70 publications

Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study

Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study

Contact Info

Product

Resources

About